200 related articles for article (PubMed ID: 32741858)
1. [Development of DDS Actively to Overcome the Blood-brain Barrier in the Region of Ischemic Stroke].
Fukuta T; Kogure K
Yakugaku Zasshi; 2020; 140(8):1007-1012. PubMed ID: 32741858
[TBL] [Abstract][Full Text] [Related]
2. [Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
Fukuta T
Yakugaku Zasshi; 2021; 141(9):1071-1078. PubMed ID: 34471008
[TBL] [Abstract][Full Text] [Related]
3. Leukocyte-mimetic liposomes possessing leukocyte membrane proteins pass through inflamed endothelial cell layer by regulating intercellular junctions.
Fukuta T; Yoshimi S; Tanaka T; Kogure K
Int J Pharm; 2019 May; 563():314-323. PubMed ID: 30978483
[TBL] [Abstract][Full Text] [Related]
4. Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Fukuta T; Ishii T; Asai T; Oku N
Biol Pharm Bull; 2019; 42(3):319-326. PubMed ID: 30828062
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte-Mimetic Liposomes Penetrate Into Tumor Spheroids and Suppress Spheroid Growth by Encapsulated Doxorubicin.
Fukuta T; Yoshimi S; Kogure K
J Pharm Sci; 2021 Apr; 110(4):1701-1709. PubMed ID: 33129835
[TBL] [Abstract][Full Text] [Related]
6. Application and Utility of Liposomal Neuroprotective Agents and Biomimetic Nanoparticles for the Treatment of Ischemic Stroke.
Fukuta T; Oku N; Kogure K
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214092
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of cerebral ischemia-reperfusion injury based on liposomal drug delivery system with asialo-erythropoietin.
Ishii T; Asai T; Oyama D; Fukuta T; Yasuda N; Shimizu K; Minamino T; Oku N
J Control Release; 2012 May; 160(1):81-7. PubMed ID: 22342472
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Cerebral Ischemia/Reperfusion Injury by Efficient Release of Encapsulated Ifenprodil From Liposomes Under Weakly Acidic pH Conditions.
Kikuchi T; Fukuta T; Agato Y; Yanagida Y; Ishii T; Koide H; Shimizu K; Oku N; Asai T
J Pharm Sci; 2019 Dec; 108(12):3823-3830. PubMed ID: 31520645
[TBL] [Abstract][Full Text] [Related]
9. Biomimetic Nanoparticle Drug Delivery Systems to Overcome Biological Barriers for Therapeutic Applications.
Fukuta T; Kogure K
Chem Pharm Bull (Tokyo); 2022; 70(5):334-340. PubMed ID: 35491189
[TBL] [Abstract][Full Text] [Related]
10. Enhanced brain delivery of hypoxia-sensitive liposomes by hydroxyurea for rescue therapy of hyperacute ischemic stroke.
Wang K; Zhou W; Jin X; Shang X; Wu X; Wen L; Li S; Hong Y; Ke J; Xu Y; Yuan H; Hu F
Nanoscale; 2023 Jul; 15(27):11625-11646. PubMed ID: 37377137
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Fukuta T; Asai T; Sato A; Namba M; Yanagida Y; Kikuchi T; Koide H; Shimizu K; Oku N
Int J Pharm; 2016 Jun; 506(1-2):129-37. PubMed ID: 27107903
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Fukuta T; Asai T; Yanagida Y; Namba M; Koide H; Shimizu K; Oku N
FASEB J; 2017 May; 31(5):1879-1890. PubMed ID: 28082354
[TBL] [Abstract][Full Text] [Related]
13. Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases.
Oku N
Biol Pharm Bull; 2017; 40(2):119-127. PubMed ID: 28154249
[TBL] [Abstract][Full Text] [Related]
14. Selective Liposomal Transport through Blood Brain Barrier Disruption in Ischemic Stroke Reveals Two Distinct Therapeutic Opportunities.
Al-Ahmady ZS; Jasim D; Ahmad SS; Wong R; Haley M; Coutts G; Schiessl I; Allan SM; Kostarelos K
ACS Nano; 2019 Nov; 13(11):12470-12486. PubMed ID: 31693858
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles accumulate in ischemic core and penumbra region even when cerebral perfusion is reduced.
Ishii T; Fukuta T; Agato Y; Oyama D; Yasuda N; Shimizu K; Kawaguchi AT; Asai T; Oku N
Biochem Biophys Res Commun; 2013 Jan; 430(4):1201-5. PubMed ID: 23268342
[TBL] [Abstract][Full Text] [Related]
16. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions.
Fukuta T; Ishii T; Asai T; Sato A; Kikuchi T; Shimizu K; Minamino T; Oku N
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):1-7. PubMed ID: 26455340
[TBL] [Abstract][Full Text] [Related]
17. Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat.
Partoazar A; Nasoohi S; Rezayat SM; Gilani K; Mehr SE; Amani A; Rahimi N; Dehpour AR
Fundam Clin Pharmacol; 2017 Apr; 31(2):185-193. PubMed ID: 27616018
[TBL] [Abstract][Full Text] [Related]
18. The permeability of puerarin loaded poly(butylcyanoacrylate) nanoparticles coated with polysorbate 80 on the blood-brain barrier and its protective effect against cerebral ischemia/reperfusion injury.
Zhao LX; Liu AC; Yu SW; Wang ZX; Lin XQ; Zhai GX; Zhang QZ
Biol Pharm Bull; 2013; 36(8):1263-70. PubMed ID: 23902970
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system.
Wang Z; Zhao Y; Jiang Y; Lv W; Wu L; Wang B; Lv L; Xu Q; Xin H
Sci Rep; 2015 Jul; 5():12651. PubMed ID: 26219474
[TBL] [Abstract][Full Text] [Related]
20. A single injection of liposomal asialo-erythropoietin improves motor function deficit caused by cerebral ischemia/reperfusion.
Ishii T; Asai T; Fukuta T; Oyama D; Yasuda N; Agato Y; Shimizu K; Minamino T; Oku N
Int J Pharm; 2012 Dec; 439(1-2):269-74. PubMed ID: 22989979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
